A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Description

This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.

Conditions

Solid Tumor, Adult

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Condition
Solid Tumor, Adult
Intervention / Treatment

-

Contacts and Locations

Gilbert

Banner Md Anderson Cancer Center, Gilbert, Arizona, United States, 85234

Sarasota

Florida Cancer Specialist (Scri) Sarasota, Sarasota, Florida, United States, 34232

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Pittsburgh

Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, United States, 15232

Sioux Falls

Avera Cancer Institue, Sioux Falls, South Dakota, United States, 57105

Nashville

Tennessee Oncology, Pllc Nashville, Nashville, Tennessee, United States, 37203

Seattle

University of Washington, Seattle, Washington, United States, 98195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
  • 2. Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
  • 3. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before the first dose of study drug(s).
  • 4. Clinically significant infection requiring systemic therapy ≤ 14 days before the first dose of study drug(s).
  • 5. Prior exposure to agents with second mitochondria-derived activator of caspases (SMAC) mimetics, or other Inhibitors of apoptosis proteins (IAPs) antagonists.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

BeiGene,

Study Record Dates

2026-11